查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
白血病治疗药的全球市场(2022年～2028年)
市场调查报告书
商品编码
1159350

白血病治疗药的全球市场(2022年～2028年)

Leukemia Therapeutic Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 125 Pages | 商品交期: 2-3个工作天内

价格

全球白血病治疗药的市场规模，在预测期间内预计以7.3％的大幅度年复合成长率成长。推动全球白血病治疗药市场成长的显着要素，是活用各种治疗方法日益进步的癌症治疗中，以需求与未满足的医疗需求为焦点。再加上研究开发的支出增加，对生活品质优势的关注高涨，政府对医疗的投资增加，为了强化药物开发的药理学进步，成为该市场的促进成长因素。

本报告提供全球白血病治疗药市场相关调查，市场概要，以及竞争情形，各市场区隔的市场，各地区分析，及企业简介等资讯。

目录

第1章 报告概要

第2章 市场概要与考察

  • 调查范围
  • 分析师的考察和目前市场趋势

第3章 竞争情形

  • 主要企业分析

第4章 市场决策要素

  • 促进因素
  • 阻碍因素
  • 机会

第5章 市场区隔

  • 全球白血病治疗药市场:各药物类型
    • 急性骨髓性白血病(AML)
    • 慢性骨髓性白血病(CML)
    • 急性淋巴性白血病(ALL)
    • 慢性淋巴性白血病(CLL)
  • 全球白血病治疗药市场:各治疗类型
    • 化疗
    • 免疫疗法
    • 标靶治疗
    • 其他

第6章 地区分析

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 全球其他地区

第7章 企业简介

  • Abbott Laboratories
  • Agios Pharmaceuticals
  • Astellas Pharma Inc.
  • Biogen Inc
  • Bristol Myers Squibb
  • Cephalon A/S
  • Daiichi Sankyo
  • Eisai Co. Ltd
  • F. Hoffmann-La Roche Ltd
  • GSK Plc
  • Innate Pharma Sa
  • Johnson & Johnson
  • Merck KGgaAa (The Merck Group)
  • Neomed Management AS
  • Novartis
  • Pfizer
  • Sanofi
  • Spectrum Pharmaceuticals Inc.
  • Viracta Therapeutics Inc.
Product Code: OMR2026473

Title: Global Leukemia Therapeutic Market Size, Share & Trends Analysis Report by Type (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia) by Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, and Others) ) Forecast 2022-2028.

The global leukemia therapeutic market is anticipated to grow at a substantial CAGR of 7.3% during the forecast period. Acute lymphocytic also known as blood cancer begins from an early version of white blood cells in the bone marrow. The term acute means that leukemia can progress very rapidly, and in case if not treated can be fatal in a few months. Cancer treatments have become advanced day by day, by the use of various therapies the demand and focusing on the unmet medical needs are the prominent factor responsible for the growth of the global leukemia therapeutics market. Moreover, increasing expenditure on research and development, rising focus on the superiority of quality of life, higher investment incurred by the government on healthcare, and advancement in pharmacology to enhance the drug development are factors propelling the growth of this market.

The global leukemia therapeutics market is segmented based on type, and treatment type. Based on type the market is bifurcated into acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, and chronic lymphocytic leukemia. Based on treatment type, the market is sub-segmented into chemotherapy, immunotherapy, targeted therapy, and others. .

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America region is anticipated to hold a major share in the global leukemia therapeutics market, due to a large number of patients pool suffering from cancer and the availability of a strong generic drug market in the emerging countries. In addition, manufacturers' interest in expanding to these North American countries, will further fuel the growth in the near future.

The major companies serving the global leukemia therapeutic market are Astellas Pharma Inc., Biogen Inc., Bristol Myers Squibb, Cephalon A/S, Daiichi Sankyo, Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Novartis, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2021, Novartis announced that the US FDA approved Scemblix(asciminib) for the treatment of chronic myeloid leukemia(CML). The FDA approved this drug for adult patients with Philadelphia chromosome-positive CML in the chronic phase(Ph+CML-CP). Moreover, Scemblix recommends that patients with CML were previously treated with two or more tyrosine kinase inhibitors(TKIs), and reduced mutations at the defective BCR-ABL 1 gene, which is associated with the over-production of leukemic cells.

 

Research Methodology

The market study of the global leukemia therapeutic market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Leukemia Therapeutic Market Research and Analysis by Types

2. Global Leukemia Therapeutic Market Research and Analysis by Drug Types

The Report Covers:

  • Comprehensive Research Methodology of the global leukemia therapeutic market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global leukemia therapeutic market.
  • Insights about market determinants that are stimulating the global leukemia therapeutic market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Leukemia Therapeutic Market
  • Recovery Scenario of Global Leukemia Therapeutic Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key CompanyAnalysis

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Leukemia Therapeutics Market by Drug Type
    • 4.1.1. Acute Myeloid Leukemia (AML)
    • 4.1.2. Chronic Myeloid Leukemia (CML)
    • 4.1.3. Acute Lymphocytic Leukemia (ALL)
    • 4.1.4. Chronic Lymphocytic Leukemia (CLL)
  • 5.2. Global Leukemia Therapeutics Market by Treatment TypeTreatment Type
    • 5.2.1. Chemotherapy
    • 5.2.2. Immunotherapy
    • 5.2.3. Targeted Therapy
    • 5.2.4. Other
      • 5.2.4.1.

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Agios Pharmaceuticals
  • 7.3. Astellas Pharma Inc.
  • 7.4. Biogen Inc
  • 7.5. Bristol Myers Squibb
  • 7.6. Cephalon A/S
  • 7.7. Daiichi Sankyo
  • 7.8. Eisai Co. Ltd
  • 7.9. F. Hoffmann-La Roche Ltd
  • 7.10. GSK Plc
  • 7.11. Innate Pharma Sa
  • 7.12. Johnson & Johnson
  • 7.13. Merck KGgaAa (The Merck Group)
  • 7.14. Neomed Management AS
  • 7.15. Novartis
  • 7.16. Pfizer
  • 7.17. Sanofi
  • 7.18. Spectrum Pharmaceuticals Inc.
  • 7.19. Viracta Therapeutics Inc.

 

LIST OF TABLES

  • 1. GLOBAL LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028($ MILLION)
  • 2. GLOBAL ACL THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL CML THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL ACL THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL CLL THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE , 2021-2028 ($ MILLION)
  • 7. GLOBAL CHEMOTHERAPY IN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL IMMUNOTHERAPY IN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 9. GLOBAL TARGETED THERAPY IN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL OTHER TRETAMENT TYPE IN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 11. GLOBAL LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028($ MILLION)
  • 12. NORTH AMERICAN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 13. NORTH AMERICAN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 14. NORTH AMERICAN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE S, 2021-2028 ($ MILLION)
  • 15. EUROPEAN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 16. EUROPEAN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 17. EUROPEAN LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE S, 2021-2028 ($ MILLION)
  • 18. ASIA-PACIFIC LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 19. ASIA-PACIFIC LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 20. ASIA-PACIFIC LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE S, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 22. REST OF THE WORLD LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 23. REST OF THE WORLD LEUKEMIA THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE S, 2021-2028 ($ MILLION)

 

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL LEUKEMIA THERAPEUTIC MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL LEUKEMIA THERAPEUTIC MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL LEUKEMIA THERAPEUTIC MARKET, 2021-2028 (%)
  • 4. GLOBAL LEUKEMIA THERAPEUTIC MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 5. GLOBAL ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL CHRONIC MYELOID LEUKEMIA (CML) THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL ACUTE LYMPHOCYTIC LEUKEMIA (ALL) THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL LEUKEMIA THERAPEUTIC MARKET SHARE BY TREATMENT TYPES, 2021 VS 2028 (%)
  • 10. GLOBAL CHEMOTHERAPY IN LEUKEMIA THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL IMMUNOTHERAPY IN LEUKEMIA THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL TARGETED THERAPY IN LEUKEMIA THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL OTHER TREATMENT TYPE LEUKEMIA THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 14. GLOBAL OTHER DRUGS FOR LEUKEMIA THERAPEUTIC MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. US LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. CANADA LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. UK LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. FRANCE LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. GERMANY LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. ITALY LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. SPAIN LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. REST OF EUROPE LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. INDIA LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. CHINALEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. JAPAN LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. SOUTH KOREA LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF ASIA-PACIFIC LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. REST OF THE WORLD LEUKEMIA THERAPEUTIC MARKET SIZE, 2021-2028 ($ MILLION)